Quick Answer
InMed Pharmaceuticals Inc. reported Cash and Equivalents of $11.08 million for fiscal year 2025.
InMed Pharmaceuticals Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $11.08M | +68.5% |
| 2024 | $6.57M | -26.3% |
| 2023 | $8.91M | +44.3% |
| 2022 | $6.18M | -16.1% |
| 2021 | $7.36M | +26.8% |
| 2020 | $5.81M | -41.0% |
| 2019 | $9.84M | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| December 31, 2025 | $6.95M | +103.4% | -25.5% |
| September 30, 2025 | $9.33M | +67.1% | -15.8% |
| June 30, 2025 | $11.08M | +68.5% | +136.7% |
| March 31, 2025 | $4.68M | -38.4% | +36.9% |
| December 31, 2024 | $3.42M | -64.1% | -38.8% |
| September 30, 2024 | $5.58M | -17.1% | -15.0% |
| June 30, 2024 | $6.57M | -26.3% | -13.5% |
| March 31, 2024 | $7.60M | -20.9% | -20.3% |
- InMed Pharmaceuticals Inc. showed an increase of +68.5% in Cash and Equivalents compared to the prior fiscal year.
- Over the 2019–2025 period, InMed Pharmaceuticals Inc.’s cash and equivalents has grown by 12.6% (from $9.84 million to $11.08 million).
- The most recent figure is from InMed Pharmaceuticals Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on September 23, 2025.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: